Jointown and JOINN Join Hands: When a Distributor Walks Upstream, 'Channels for Assets' Becomes CXO Integration's Second Path

On the evening of 29 October, Jointown Pharmaceutical (600998) announced a four-party strategic cooperation agreement with JOINN Laboratories (603127.SH / 06127.HK), JOINN Biologics and Sheng Tong Intelligence, covering commissioned R&D, market access and sales, early-stage incubation, AI for healthcare, and industrial park development. Jointown frames it as a new 'CRO + CDMO + CSO' integrated model, with the explicit aim of securing sales and distribution rights for quality innovative and high-end generic drugs by entering early-stage development. It mirrors the WuXi and Pharmaron route: one walks from the lab toward commercialisation, the other reverses in from the channel.

On the evening of 29 October, Jointown Pharmaceutical Group (600998) announced a strategic cooperation agreement with JOINN Laboratories (603127.SH / 06127.HK), Beijing JOINN Biologics and Sheng Tong Intelligence (Beijing). The language is deliberately modest — a framework document, no material impact on 2026 results, specific projects to be contracted separately — but the direction is worth recording: a company whose core business is pharmaceutical distribution is pushing into drug discovery, preclinical evaluation, CDMO and AI-enabled R&D.

Jointown describes the combination as a new integrated "CRO + CDMO + CSO" drug value-service model, and states its motive plainly: by entering early-stage development, it aims to secure sales and distribution rights for quality innovative drugs and high-end generics.

What the agreement actually contains

Five blocks. First, commissioned R&D: Jointown identifies projects in innovative drugs, generics and improved new drugs based on market demand, and commissions partners to develop them — note the direction of the relationship, with project origination sitting with Jointown and R&D capability with JOINN. Second, sales: Jointown provides reimbursement negotiation, market access, distribution and terminal sales support to partners' clients. Third, early-stage investment and incubation, through a jointly built channel. Fourth, AI for healthcare: jointly constructing datasets spanning R&D and sales. Fifth, an industrial park intended to align discovery, pilot production, manufacturing and distribution along one chain.

The fifth block carries the largest subtext. Co-locating discovery, pilot, manufacturing and distribution effectively compresses the physical distance between a molecule's inception and a hospital shelf to a few kilometres. That has been the standard pitch of Chinese biopharma parks for a decade, but a distributor leading it and wiring its delivery network directly into the park is a newer configuration.

Three partners, three roles

JOINN Laboratories is the listed entity, focused on non-clinical toxicology, clinical trials, pharmacovigilance and laboratory animals, and is a leading player in Chinese safety assessment, dual-listed in Shanghai and Hong Kong. JOINN Biologics is a separate legal person: founded in 2019 with RMB 560m in registered capital, it operates CDMO pilot and manufacturing bases in Beijing, Guangzhou and overseas covering large-molecule biologics and high-potency small-molecule dosage forms, and shares the same legal representative, Feng Yuxia. In other words, the actual CDMO capacity in this agreement belongs to JOINN Biologics, not the listed JOINN Laboratories — they are related parties, not the same reporting entity, and the distinction matters when reading the announcement.

Sheng Tong Intelligence, founded in 2018 with about RMB 11.58m in registered capital, focuses on AI for Science and claims more than 2,000 algorithms available as services. Its role here is to supply model capability to both the R&D and sales ends and to help build the datasets.

Integration, in the opposite direction

For a decade the CXO industry's integration story ran the WuXi and Pharmaron way: enter at discovery (R), extend into development (D) and manufacturing (M), use the enormous compound flow at the front to feed the back end, and monetise at commercial projects with high margins. WuXi AppTec's 2026 nine-month numbers make the case: more than 450,000 compounds delivered in the past twelve months, 314 molecules converted from R to D, and small-molecule D&M revenue of RMB 23.58bn (+65.6%). That is the lab-to-factory-to-patient route.

Jointown's route is reversed: patient, hospital, factory, lab. It already holds terminal coverage and distribution — the CSO chassis — but lacks products; JOINN Biologics holds capacity and R&D capability but lacks an order funnel and a commercial channel. The joint where they meet is product rights: not capacity leasing, not service outsourcing, but a claim on the sales end once a drug is approved.

That explains why investment incubation and sales rights sit at equal weight in the agreement. R&D spending is a cost, sales rights are the return, and incubation is the mechanism that aligns the two time horizons.

Why now

Three conditions hold simultaneously. First, the policy environment favours domestic closure: after the October 2026 joint notice from MOFCOM and MOST placing certain biopharma technologies under export-control consultation, services and capacity are pivoting toward domestic demand — and the binding constraint in domestic demand is not capacity but products and payer access. Second, mid-tier CDMOs are hungry for orders: utilisation at non-listed platforms such as JOINN Biologics depends heavily on deal flow, and partnering with a distributor is the cheapest form of customer acquisition. Third, out-licensing has turned product rights into a priceable, tradeable asset — China's out-licensing total has crossed the hundred-billion-dollar order of magnitude, repeatedly re-anchoring valuations for early-stage molecules and making "invest early, take sales rights" arithmetically viable.

Editor's note: the weight of a framework, measured by three follow-up actions

It must be said plainly: this is a non-binding framework. The announcement itself states that specific projects will be negotiated separately and that there is no material impact on 2026 results. The industry signs hundreds of such agreements each year, most of which end as a press release.

The real signal therefore lies not in the signing but in three follow-up actions. One: does a specific molecule emerge, originated by Jointown and developed by JOINN, with disclosed milestone terms. Two: does joint investment appear, meaning Jointown actually commits capital to an early programme rather than merely offering a channel. Three: does JOINN Biologics book disclosable new orders or report better utilisation as a result. Any one of the three would validate the route.

If validated, the implication for the CXDMO industry is structural: the competitive axis of integration may shift from "whose capacity is larger and whose technology broader" to "who holds both R&D capability and terminal access". That is bad news for pure-capacity CDMOs, which will increasingly resemble toll manufacturers squeezed from both the channel and the product side. It is an opportunity for companies with commercial access, because for the first time they can use the ability to sell as negotiating leverage upstream.